Compare ETON & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | POET |
|---|---|---|
| Founded | 2017 | 1972 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2018 | 2008 |
| Metric | ETON | POET |
|---|---|---|
| Price | $52.31 | $5.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $71.50 | N/A |
| AVG Volume (30 Days) | 428.5K | ★ 7.3M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $87.26 | $211.20 |
| Revenue Next Year | $47.21 | $2,864.45 |
| P/E Ratio | $131.15 | ★ N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $14.27 | $3.87 |
| 52 Week High | $66.37 | $20.65 |
| Indicator | ETON | POET |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 31.68 |
| Support Level | $48.58 | N/A |
| Resistance Level | $57.00 | $6.23 |
| Average True Range (ATR) | 2.39 | 0.34 |
| MACD | 0.27 | -0.00 |
| Stochastic Oscillator | 47.46 | 10.55 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.